-transparent.png){kind=logo}
Antitumor activity of human lymphoblastoid interferon (HLBI) in advanced renal cell carcinoma was studied. Intramuscular injection at a dose of 3 X 10(6) IU was given daily to 18 patients, including 14 patients who had undergone nephrectomy and 4 patients who had not undergone the procedure. One patient (5.6%) showed complete remission; 2 patients (11.1%) minor remission, 8 patients (44.4%) stable disease, and 7 patients (38.9%) progression. Three responders were the patients who had had nephrectomy, and whose metastatic sites were lung. Tumor responses were observed in patients with renal cell carcinoma of clear cell type or mixed type of clear cells and granular cells. We concluded that interferon has a potential antitumor activity in selected patients with advanced renal cell carcinoma.
K Marumo, and
M Murai, and
M Hayakawa, and
H Tazaki
February 1988,
The Journal of urology,
K Marumo, and
M Murai, and
M Hayakawa, and
H Tazaki
May 1984,
Hinyokika kiyo. Acta urologica Japonica,
K Marumo, and
M Murai, and
M Hayakawa, and
H Tazaki
November 1992,
Hinyokika kiyo. Acta urologica Japonica,
K Marumo, and
M Murai, and
M Hayakawa, and
H Tazaki
June 1987,
Nihon Gan Chiryo Gakkai shi,
K Marumo, and
M Murai, and
M Hayakawa, and
H Tazaki
August 2005,
Hinyokika kiyo. Acta urologica Japonica,
K Marumo, and
M Murai, and
M Hayakawa, and
H Tazaki
January 1996,
International journal of urology : official journal of the Japanese Urological Association,
K Marumo, and
M Murai, and
M Hayakawa, and
H Tazaki
May 1997,
The Journal of urology,
K Marumo, and
M Murai, and
M Hayakawa, and
H Tazaki
January 1985,
Cancer treatment reports,
K Marumo, and
M Murai, and
M Hayakawa, and
H Tazaki
March 1987,
Cancer,
K Marumo, and
M Murai, and
M Hayakawa, and
H Tazaki
January 1989,
Progress in clinical and biological research,
